Literature DB >> 28273386

Performance of the Pooled Cohort atherosclerotic cardiovascular disease risk score in hepatitis C virus-infected persons.

K W Chew1, D Bhattacharya1, T B Horwich1, P Yan2,3, K A McGinnis2, C Tseng1, M S Freiberg4,5, J S Currier1, A A Butt2,6,7,8,9.   

Abstract

Chronic hepatitis C virus (HCV) infection has been associated with an increased risk for cardiovascular disease (CVD). The recommended Pooled Cohort atherosclerotic cardiovascular disease (ASCVD) risk equation for estimation of 10-year CVD risk has not been validated in HCV-infected populations. We examined the performance of the ASCVD risk score in HCV-infected persons, using the national Electronically Retrieved Cohort of HCV Infected Veterans to derive a cohort of HCV-infected and uninfected subjects without baseline ASCVD, hepatitis B, or HIV infection, and with low-density lipoprotein cholesterol level<190 mg/dL. Performance of the ASCVD risk equation was assessed by Cox proportional hazard regression, C-statistics and Hosmer-Lemeshow statistic. The cohort included 70 490 HCV-infected and 97 766 HCV-uninfected men with mean age of 55 years, 56% White and 29% Black. Incident CVD event rates were similar between the two groups (13.2 and 13.4 events/1000 person-years), with a higher incidence of coronary heart disease events in the HCV-uninfected group and of stroke events in the HCV-infected group. Adjusting for ASCVD risk score, HCV infection was associated with higher risk for an ASCVD event in the subgroup with baseline ASCVD risk ≥7.5% (HR: 1.19, P<.0001). C-statistics were poor in both the HCV-infected and uninfected groups (0.60 and 0.61, respectively). By Hosmer-Lemeshow test, the ASCVD risk equation overestimated risk amongst lower risk patients and underestimated risk amongst higher risk patients in both the HCV-infected and uninfected groups. Further investigation is needed to determine whether a modified equation to accurately predict ASCVD risk in HCV-infected persons is warranted.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  atherosclerotic cardiovascular disease score; cardiovascular disease; cardiovascular risk assessment; hepatitis C virus

Mesh:

Year:  2017        PMID: 28273386      PMCID: PMC5589479          DOI: 10.1111/jvh.12705

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  23 in total

Review 1.  Cardiovascular diseases and HCV infection: a simple association or more?

Authors:  Salvatore Petta; Fabio Salvatore Macaluso; Antonio Craxì
Journal:  Gut       Date:  2013-12-02       Impact factor: 23.059

2.  2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson; Harmon S Jordan; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

3.  Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis.

Authors:  Luigi E Adinolfi; Luciano Restivo; Rosa Zampino; Barbara Guerrera; Amedeo Lonardo; Laura Ruggiero; Francesco Riello; Paola Loria; Anna Florio
Journal:  Atherosclerosis       Date:  2012-02-08       Impact factor: 5.162

4.  Development and verification of a "virtual" cohort using the National VA Health Information System.

Authors:  Shawn L Fultz; Melissa Skanderson; Larry A Mole; Neel Gandhi; Kendall Bryant; Stephen Crystal; Amy C Justice
Journal:  Med Care       Date:  2006-08       Impact factor: 2.983

5.  Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans.

Authors:  A A Butt; U A Khan; K A McGinnis; M Skanderson; C Kent Kwoh
Journal:  J Viral Hepat       Date:  2007-12       Impact factor: 3.728

Review 6.  Safety of statin therapy in patients with preexisting liver disease.

Authors:  Mihai Daniel Onofrei; Kristina L Butler; Dawn C Fuke; Heather B Miller
Journal:  Pharmacotherapy       Date:  2008-04       Impact factor: 4.705

7.  Hepatitis C virus RNA localization in human carotid plaques.

Authors:  Maria Boddi; Rosanna Abbate; Benedetta Chellini; Betti Giusti; Carlo Giannini; Giovanni Pratesi; Luciana Rossi; Carlo Pratesi; Gian Franco Gensini; Laura Paperetti; Anna Linda Zignego
Journal:  J Clin Virol       Date:  2009-11-05       Impact factor: 3.168

8.  Comparison of two VA laboratory data repositories indicates that missing data vary despite originating from the same source.

Authors:  Kathleen A McGinnis; Melissa Skanderson; Forrest L Levin; Cynthia Brandt; Joseph Erdos; Amy C Justice
Journal:  Med Care       Date:  2009-01       Impact factor: 2.983

9.  Hepatitis C virus infection and the risk of coronary disease.

Authors:  Adeel A Butt; Wang Xiaoqiang; Matthew Budoff; David Leaf; Lewis H Kuller; Amy C Justice
Journal:  Clin Infect Dis       Date:  2009-07-15       Impact factor: 9.079

10.  Is hepatitis C associated with atherosclerotic burden? A systematic review and meta-analysis.

Authors:  He Huang; Rongyan Kang; Zhendong Zhao
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

View more
  4 in total

1.  Liver Fibrosis Progression and Mortality in Hepatitis B- and C-Coinfected Persons Treated With Directly Acting Antiviral Agents: Results From ERCHIVES.

Authors:  Adeel A Butt; Peng Yan; Samia Aslam; Abdul-Badi Abou-Samra; Kenneth E Sherman; Obaid S Shaikh
Journal:  Clin Infect Dis       Date:  2020-07-27       Impact factor: 9.079

Review 2.  Cardiovascular Implications of Immune Disorders in Women.

Authors:  Caitlin A Moran; Lauren F Collins; Nour Beydoun; Puja K Mehta; Yetunde Fatade; Ijeoma Isiadinso; Tené T Lewis; Brittany Weber; Jill Goldstein; Igho Ofotokun; Arshed Quyyumi; May Y Choi; Kehmia Titanji; Cecile D Lahiri
Journal:  Circ Res       Date:  2022-02-17       Impact factor: 23.213

3.  Cardiovascular Risk in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals.

Authors:  Mohammad Said Ramadan; Filomena Boccia; Simona Maria Moretto; Fabrizio De Gregorio; Massimo Gagliardi; Domenico Iossa; Emanuele Durante-Mangoni; Rosa Zampino
Journal:  J Clin Med       Date:  2022-09-29       Impact factor: 4.964

4.  Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study.

Authors:  Kuan Ken Lee; Dominik Stelzle; Rong Bing; Mohamed Anwar; Fiona Strachan; Sophia Bashir; David E Newby; Jasmit S Shah; Michael H Chung; Gerald S Bloomfield; Chris T Longenecker; Shashwatee Bagchi; Shyamasundaran Kottilil; Sarah Blach; Homie Razavi; Peter R Mills; Nicholas L Mills; David A McAllister; Anoop S V Shah
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-07-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.